2018 ISV ANNUAL CONGRESS

28th-30th OCTOBER • ATLANTA, GA

ORAL PROGRAM			
SUNDAY OCTOBER 28, 2018			
08:00-09:15	REGISTRATION		
08:30-09:45	WELCOME COFFEE *(Marquis Foyer)* SPONSORED BY: GlaxoSmithKline (GSK)		
09:45-09:55	CONGRESS CO-CHAIRS OPENING REMARKS (*Marquis Salon A)* ISV Congress co-Chairs: Ted Ross, *University of Georgia*; Denise Doolan, *James Cook University*		
9:55-10:00	INTRODUCTION OF OPENING SESSION AND SPEAKER (*Marquis Salon A)* David Weiner, *ISV President*		
10:00-10:45	Creating Vaccine Confidence: Courage, Conviction, and Compassion (*Marquis Salon A)* Julie Gerberding, *Merck and Co.* and *US CDC Director (2002-2009)*		
10:45-12:00	PLENARY SESSION 1: Influenza 1918 to 2018 *(Marquis Salon A)* Session Chairs: Ted Ross, *University of Georgia*; Rafi Ahmed, *Emory University*		
10:45-11:10	[PL1.1] Where did the Spanish Influenza come from and could its killing power have been thwarted by the "new" vaccines in 1918? John Oxford, *Queen Mary College*		
11:10-11:35	[PL1.2] Pathogenesis of the 1918 Pandemic Virus Terrence Tumpey, *Centers for Disease Control and Prevention*		
11:35-12:00	[PL1.3] Influenza Vaccine Effectiveness: What's the Problem with H3N2? Edward Belongia, *Marshfield Clinic Research Institute*		
12:00-13:30	LUNCH *(Skyline – 10th Floor)* SPONSORED BY: INOVIO PHARMACEUTICALS		
13:30-15:45	CONCURRENT SESSION 1 Vaccine Technologies, Formulations, and Delivery *(International 8)* Session Chairs: Mark Prausnitz, *Georgia Tech University* Karl Ljundgberg, *Karolinska Institutet*	CONCURRENT SESSION 2 Neoantigens, Cancer Vaccines, and More *(International 9)* Session Chairs: Nikolai Petrovsky, *Flinders University* Randy Albrecht, *Mount Sinai School of Medicine*	CONCURRENT SESSION 3 Non-Viral Vaccines *(International 10)* Session Chairs: Linda Klavinskis, *King's College London* Suh-Chin Wu *National Tsing Hua University*
13:30-13:55	[O1.1] Developing Vaccines that Elicit Broadly Neutralizing Antibodies Ravi Kane, *Georgia Tech University*	[O2.1] Immunogenicity of Neoantigen Cancer Vaccines Hyewon Phee, *Amgen*	[O3.1] Toward licensure of the first and future generations of live parasite *Plasmodium falciparum* sporozoite (PfSPZ) vaccines Thomas Richie, *Sanaria*
13:55-14:20	[O1.2] Microneedle Patch as a New Vaccine Delivery Method Nadine Rouphael, *Emory University*	[O2.2] Advances in the field of in-silico methods for the identification of (neo)epitopes. Morten Nielsen, *The Technical University of Denmark*	[O3.2] Autophagy: a New Strategy for Host-directed Therapy of Tuberculosis Eun-Kyoung Jo, *Chungnam National University School of Medicine*
14:20-14:35	[O1.3] Immunogenicity of a protective intradermal DNA vaccine against Lassa Virus in Cynomolgus Jingjing Jiang, *Inovio Pharmaceuticals*	[O2.3] Beyond Adjuvants: Vaccines for Cancer Immunotherapy and Infectious Disease Young Taik Lim, *Sungkyunkwan University* →(14:20-14:45)←	[O3.3] Replicating Single Cycle Adenovirus Vaccine against Clostridium Difficile William Matchett, *Mayo Clinic*

14:35-14:50	[O1.4] Genomic DNA as a damage - associated molecular pattern increases the immunogenicity of influenza vaccines given by a dissolvable microneedle patch Teena Mohan, *Georgia State University*	[O2.4] Development of a novel multi-level anti-cancer vaccine using mimotopes of anti-Her-2/neu antibodies in combination with immune checkpoint inhibitors Joshua Tobias, *Medical University of Vienna* →(14:45-15:00)←	[O3.4] Vaccine-induced immunity in the immunocompromised host: Evaluating antifungal vaccine efficacy in a non-human primate model of drug-induced immunosuppression Viviana Cobos Jimenez, *University of Georgia*
14:50-15:05	[O1.5] A Single-cycle Adenovirus Vaccine against Ebola Virus Stephanie Anguiano-Zarate, *Mayo Clinic*	[O2.5] Development of Vaccines for Infectious Diseases and Cancer Using a Novel MVA-VLP Vector Arban Domi, *GeoVax, Inc.* →(15:00-15:15)←	[O3.5] To what Extent Are Recent Pertussis Epidemics Due to Under Vaccination or to Waning of Pertussis Vaccine Immunity? Ousseny Zerbo, *Kaiser Permanente*
15:05-15:20	[O1.6] Immunogenicity and Efficacy of a Thermostable Live-Attenuated Influenza Vaccine in Ferrets Jasmina Luczo, *University of Georgia*	[O2.6] Longitudinal Assessment of Memory B cell and Plasmablast Reactivity Against Influenza A Hemagglutinin in Subjects of Varying Age Rodrigo Abreu, *, University of Georgia* →(15:15-15:30)←	[O3.6] Microneedle-based Novel Transdermal Gonorrhea Vaccines Lotika Bajaj, *Mercer University*
15:20-15:35	[O1.7] Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses Lei Deng, *Georgia State University*	[O2.7] A DNA-based immunotherapy induces receptor-blocking antibodies that can neutralize HBV in humanized mice Lars Frelin, *Karolinska Institutet* →(15:30-15:45)←	[O3.7] Design of a multi-antigenic, multi-stage and multi-epitope potential vaccine candidate against onchocerciasis and related filarial diseases: adding immunoinformatics to immunomics Robert Adamu Shey, *Universite Libre de Bruxelles*
15:45-16:15	COFFEE BREAK *(Marquis Foyer/Marquis Salon B)* SPONSORED BY: GEORGIA RESEARCH ALLIANCE		
16:15-18:10	PLENARY SESSION 2: Host Immune Response to Vaccination *(Marquis Salon A)* Session Chairs: Shan Lu, *UMass Medical School*; Maria Issagouliantis, *Riga Stradins University*		
16:15-16:40	[PL2.1] Vaccines and Immune Memory Rafi Ahmed, *Emory University*		
16:40-17:05	[PL2.2] Profiling the IgOme - the repertoire of antibodies in serum: *principles and applications* Johnathan Gershoni, *Tel Aviv University*		
17:05-17:30	[PL2.3] Understanding Innate Immune Mechanisms Dictating Vaccine Responses Karen Loré, *Karolinska Institutet*		
17:30-17:55	[PL2.4] The History of Pertussis and Pertussis Vaccines; Mistakes Made during a 112-Year Odyssey and What some of those Mistakes Bode for the Future James Cherry, *University of California, Los Angeles*		
17:55-18:10	[PL2.5] Skin immunisation harnesses networks of protective immune connectivity in peripheral tissues Linda Klavinskis, *King's College London*		
18:10-20:00	POSTER SESSION # 1 *(Marquis Salon B)*		
18:30-20:00	WELCOME RECEPTION *(Marquis Foyer/Marquis Salon B)* SPONSORED BY: EpiVax, Inc.		

MONDAY OCTOBER 29, 2018			
07:30-08:30	MORNING COFFEE *(Marquis Foyer)* SPONSORED BY: MERCK		
08:30-10:10	PLENARY SESSION 3: Human Vaccine Trials *(Marquis Salon A)* Session Chairs: Julia Hilliard, *Georgia State University*; Annie DeGroot, *EpiVax, Inc.*		
08:30-08:55	[PL3.1] The State of Vaccine Development Against the Human Cytomegalovirus Stanley Plotkin, *Vaxconsult*		
08:55-09:20	[PL3.2] Lymphoid tissue fibrosis is associated with impaired vaccine responses Tim Schacker, *University of Minnesota*		
09:20-09:45	[PL3.3] Vaccines for Herpes Zoster Tony Cunningham, *The Westmead Institute for Medical Research and University of Sydney*		
09:45-10:10	[PL3.4] Systems Biology in Vaccine Trials Nadine Rouphael, *Emory University*		
10:10-10:40	COFFEE BREAK *(Marquis Foyer/Marquis Salon B)* SPONSORED BY: GC PHARMA		
10:40-12:30	CONCURRENT SESSION 4 Viral Vaccines *(International 8)* Session Chairs: Mark Connors, *NIAID* Lars Frelin, *Karolinska Institutet*	CONCURRENT SESSION 5 E-RID Vaccines *(International 9)* Session Chairs: Ed Rybicki, *University of Cape Town* Paul Duprex, *Boston University School of Medicine*	CONCURRENT SESSION 6 Vaccine Evaluation *(International 10)* Session Chairs: Jeffrey Ulmer, *GlaxoSmithKline* Karen Norris, *University of Georgia*
10:40-11:05	[O4.1] A Replication Defective Human Cytomegalovirus as a Vaccine for Prevention of Congenital Infection Tong Ming Fu, *Merck Research Laboratories*	[O5.1] Innovative vaccination methods Gary Kobinger, *Université Laval*	[O6.1] CD40L-adjuvanted HIV Vaccines Induce Broad Neutralizing Antibody Responses in Macaques Rama Rao Amara, *Emory University*
11:05-11:30	[O4.2] Engineering immunogenicity: novel live attenuated vaccines against pneumoviruses Martin Moore, *Meissa Vaccines*	[O5.2] Rift Valley Fever control through vaccination: an ongoing challenge in endemic regions Baptiste Dungu, *MCI Sante Animale*	[O6.2] Development of therapeutic vaccines for cardiovascular diseases Hironori Nakagami, *Osaka University*
11:30-11:45	[O4.3] Efficacy of RSV Maternal Immunization Varies with the Version of the Pre-fusion F Antigen in Virus-like Particles (VLPs) Trudy Morrison, *University of Massachusetts Medical School*	[O5.3] Towards the development of influenza virus vaccines: insights from the ferret animal model Randy Albrecht, *Icahn School of Medicine at Mount Sinai*	[O6.3] Is the current dose of normal human immunoglobulin for post-exposure prophylaxis of measles in Australia too low? Megan Young, *Griffith University*
11:45-12:00	[O4.4] Novel RSV vaccine development protect adult and neonate animals Bin Wang, *Fudan University*	[O5.4] Age-Related Modulation of Immune Response to Vaccination with a Chikungunya Virus-Like Particle Vaccine and Chikungunya Viral Infection Maria Arevalo, *University of Georgia*	[O6.4] Variation in direct and indirect effectiveness and total impact of infant rotavirus vaccination among children in the United States: analysis of national claims data from 2001-2016 Julia Baker, *Emory University*

12:00-12:15	[O4.5] Unraveling the respiratory syncytial virus (RSV) antibody functional repertoire in adult healthy donors Emanuele Andreano, *University of Siena (IT)*	[O5.5] A Universal Dengue Vaccine Elicits Neutralizing Antibodies Against Strains from All Four Dengue Serotypes Naoko Uno, *University of Georgia*	[O6.5] Estimating the population-level effect of pediatric norovirus vaccination: A model simulation study Elizabeth Sajewski, *Emory University*
12:15- 12:30	[O4.6] Elicitation of protective antibodies against 20 years of future H3N2 co-circulating influenza virus variants in ferrets imprinted to historical H3N2 influenza viruses James Allen, *University of Georgia*	[O5.6] Multiroute morbillivirus entry: disease informs delivery Paul Duprex, *Boston University School of Medicine*	[O6.6] Status of Immunity against Polio Virus among Individuals in Three Regions of Ghana, 2017. Joseph Opare, *Ghana Health Service/ Ministry of Health*
12:30-13:30	LUNCH *(Skyline – 10th Floor)* SPONSORED BY: VGXI, Inc.		
13:00-14:30	POSTER SESSION # 2 *(Marquis Salon B)*		
14:00-15:00	ISV ANNUAL MEETING *(Marquis Salon A)*		
15:00-15:30	COFFEE BREAK *(Marquis Foyer/Marquis Salon B)* SPONSORED BY: HIVF		
15:30-17:50	PLENARY SESSION 4: Vaccines for Influenza Viruses *(Marquis Salon A)* Session Chairs: Mark Tompkins, *University of Georgia*; Sang-Moo Kang, *Georgia State University*		
15:30-15:55	[PL.4.1] Systems Profiling of Fluzone™ Vaccinees – Biomarkers of Breadth & Durability Harold Kleanthous, *Sanofi Pasteur*		
15:55-16:20	[PL4.2] New insights into mucosal vaccine adjuvant functions that can be explored for developing broadly protective influenza vaccines Nils Lycke, *University of Gothenburg*		
16:20-16:35	[PL4.3] VaxArray Neuraminidase: A new assay for neuraminidase quantification of seasonal influenza vaccines Rose Nash, *InDevR*		
16:35-16:50	[PL4.4] An alternative strategy as a quadrivalent live attenuated influenza virus vaccine Zhimin Wan, *University of Georgia*		
16:50-17:05	[PL4.5] Molecular Dissection of the Antibody Response Elicited by a Computationally Optimized Broadly Reactive Antigen (COBRA) H1 Hemagglutinin Influenza Vaccine Giuseppe Andrea Sautto, *University of Georgia*		
17:05-17:20	[PL4.6] Pan-influenza A protection by prime-boost vaccination with X-31 cold-adapted live attenuated influenza vaccine Baik Seong, *Yonsei University*		
17:20-17:35	[PL4.7] Development of paradigm-shifting T cell-targeting universal influenza vaccines Daniel Hoft, *Saint Louis University*		
17:35-17:50	[PL4.8] Robust Cellular Immune Responses and Cross-Protective Anti-Hemagglutination Responses Elicited by Influenza Micro-Consensus DNA Vaccines Anna Slager, *Inovio Pharmaceuticals*		
17:50-18:20	BUS PICK UP FOR GALA DINNER *(Main Entrance)*		
18:30-22:00	GALA DINNER *(TICKETS REQUIRED)* SPONSORED BY: VGXI, Inc. and GEORGIA RESEARCH ALLIANCE		

TUESDAY OCTOBER 30, 2018			
07:30-08:30	MORNING COFFEE *(Marquis Foyer)* SPONSORED BY: CELLULAR TECHNOLOGY LIMITED (CTL)		
08:30-10:10	PLENARY SESSION 5: Public Health, Public Policy, and Vaccine Acceptance *(Marquis Salon A)* Session Chairs: Margaret Liu, *ProTherImmune*; David Weiner, *The Wistar Institute*		
08:30-08:55	[PL5.1] Vaccine hesitancy – the global landscape Pauline Patterson, *London School of Hygiene & Tropical Medicine (LSHTM)*		
08:55-09:20	[PL5.2] Fostering Vaccine and Immunization Acceptance: Insights from Communication Practice and Research Glen Nowak, *University of Georgia*		
09:20-09:45	[PL5.3] Vaccine associated-hypersensitivity Michael McNeil, *Centers for Disease Control and Prevention*		
09:45-10:10	[PL5.4] Global strategy of Polio eradication: Russian experience Aydar Ishmukhametov, *Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products*		
10:10-10:40	COFFEE BREAK *(Marquis Foyer/Marquis Salon B)* SPONSORED BY: SANOFI PASTEUR		
10:40-12:20	CONCURRENT SESSION 7 Immunodulators and Vaccines *(International 8)* Session Chairs: Ali Harandi, *University of Gothenburg* Joon Haeng Rhee *Chonnam National University Medical School*	CONCURRENT SESSION 8 One Health and Vet Vaccines *(International 9)* Session Chairs: Anna-Lise Williamson, *University of Cape Town* Jarrod Mousa, *University of Georgia*	CONCURRENT SESSION 9 HIV/AIDS *(International 10)* Session Chairs: Janet McNicholl, *Centers for Disease Control and Prevention* Barbara Felber, *National Cancer Institute*
10:40-11:05	[O7.1] Vaccination against chronic diseases using virus-like particles Martin Bachmann, *Jenner Institute*	[O8.1] Nanoparticle technologies that help drive bovine immune responses in East Coast fever vaccine development Vish Nene, *International Livestock Research Institute (ILRI)*	[O9.1] Humoral responses to HIV-1: building the paths to a protective vaccine Guido Ferrari, *Duke University School of Medicine*
11:05-11:20	[O7.2] A Multi-Omics Systems Analysis of Human Vaccine Adjuvants: Of Clouds and Clocks Ali Harandi, *University of Gothenburg*	[O8.2] African Horse Sickness Virus-Like Particle Vaccine Candidate Made in Plants Edward Rybicki, *Biopharming Research Unit, University of Cape Town*	[O9.2] Needle-free injection of the sublingual and buccal tissues with an HIV-1 vaccine induces strong systemic and mucosal immune responses and protects from SHIV challenge in rhesus macaques Andrew Jones, *Emory University*
11:20-11:35	[O7.3] Human clinical data on use of Advax delta inulin adjuvants in infectious disease, allergy and cancer vaccines Nikolai Petrovsky, *Flinders University*	[O8.3] Vaccination and intra-cage transmission of a recombinant parainfluenza virus 5 expressing Rabies lyssavirus glycoprotein in the big brown bat (Eptesicus fuscus) Kelsey Briggs, *University of Georgia*	[O9.3] DNA+Protein HIV vaccine protection against SHIV challenge upon same site administration in macaques Barbara Felber, *National Cancer Institute*

11:35-11:50	[O7.4] Vaccine adjuvant effects of dendritic cell-targeting peptides Yasuo Yoshioka, *Osaka University*	[O8.4] Rational design of Lumpy Skin Disease Virus Vaccines Anna-Lise Williamson, *University of Cape Town*	[O9.4] Direct Detection of Cross-clade ADCC activities in human volunteer sera elicited by a polyvalent DNA prime-protein boost HIV vaccine DP6-001 Shixia Wang, *University of Massachusetts Medical School*
11:50-12:05	[O7.5] Cellular and Humoral Immune Responses to PENNVAX-GP® HIV DNA Vaccine plus IL-12 are Equivalent or Superior when Delivered by Intradermal vs. Intramuscular Electroporation in Healthy, HIV Uninfected Adults Srilatha Edupuganti, *Emory University*	[O8.5] Laser-assisted skin delivery of immuno-contraceptive rabies nanoparticulate vaccine in poloxamer gel Amit Bansal, *Mercer University*	[O9.5] Synthetic DNA Delivery by Electroporation Promotes Robust in vivo Post-Translational Modification of Broadly Neutralizing anti-HIV Immunoadhesin Ziyang Xu, *Wistar Institute*
12:05-12:20	[O7.6] Augmentation of antigenicity of the C-terminal region of Clostridium perfringens enterotoxin by fusion with the B subunit of Escherichia coli Shiga toxin 2 for the development of bivalent food poisoning vaccine Koji Hosomi *National Institutes of Biomedical Innovation, Health and Nutrition*	[O8.6] Identification of candidate Coxiella burnetii T cell epitopes for a novel human Q fever vaccine Lenny Moise, *EpiVax*	[O9.6] Liposome-Encapsulated HIV-1 gp120 Induces Potent V1V2-Specific Antibodies in Humans Mangala Rao, *USMHRP* *Walter Reed Army Institute of Research*
12:20-13:20	LUNCH *(Skyline – 10th Floor)*		SPONSORED BY: PFIZER, Inc.
13:20-14:00	Career Development Panel		*(International 8)*
14:00-14:30	ISV Award Ceremony		*(Marquis Salon A)*
14:30-16:00	PLENARY SESSION 6: The Future of Vaccines Session Chairs: Denise Doolan, *James Cook University*; Trudy Morrison, *University of Massachusetts Medical School*		*(Marquis Salon A)*
14:30-14:55	[PL6.1] Nasal Vaccines for the Prevention of Respiratory Infection Hiroshi Kiyono, *University of Tokyo*		
14:55-15:10	[PL6.2] Stabilized HIV-1 Envelope Designs Expressed in a Replication Competent Ad4 Vector Directly Impact Envelope Conformation, Expression, and Immunogenicity Mark Connors, *NIAID*		
15:10-15:25	[PL6.3] An mRNA based trivalent genital herpes vaccine: Sterilizing immunity as a real possibility Harvey Friedman, *University of Pennsylvania*		
15:25-15:40	[PL6.4] Why Are CD8 T Cell Epitopes of Human Influenza Virus Conserved? Zheng-Rong Li, *Emory University*		
15:40-15:55	[PL6.5] Pandemic Influenza Preparedness: Thailand as part of Global Action Plan to be one of the local Influenza Vaccine Development Punnee Pitisuttithum, *Mahidol University*		
16:00-16:15	CLOSING REMARKS AND INTRODUCTION TO 2019 CONGRESS		*(Marquis Salon A)*